Merck (MRK) Announces FDA Approves KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L

Merck (MRK) Announces Positive CHMP Opinion for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the... More